Indication
Peripheral T-cell Lymphoma
34 clinical trials
57 products
7 drugs
Clinical trial
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced MalignanciesStatus: Terminated, Estimated PCD: 2023-12-01
Clinical trial
A Phase II, Open-label, Single-arm, Multicenter Study of Chidamide in Patients With Relapsed or Refractory Peripheral T-cell LymphomaStatus: Recruiting, Estimated PCD: 2025-12-01
Product
ChidamideProduct
SHR2554/CHOPProduct
SHR2554/CHOEPClinical trial
A Phase Ib/II, Open-label, Multi-center Study of SHR2554 With CHOP/CHOEP in Treatment-naïve Patients With Peripheral T-cell LymphomaStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Product
SEA-TGTProduct
sasanlimabProduct
Brentuximab vedotinProduct
DuvelisibClinical trial
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Status: Completed, Estimated PCD: 2023-12-22
Clinical trial
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 ExpressionStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Product
cyclophosphamideProduct
prednisoneProduct
doxorubicinProduct
Brentuximab VedotinProduct
GFH009Clinical trial
A Phase Ib/II, Multicentre, Open-label Study to Assess the Efficacy, Safety/ Tolerability and Pharmacokinetic of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase 1, First-In-Human, Open-Label, Dose-Escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Intravenous Doses of BITR2101 (Anti-TNFR2) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Including Cutaneous and Peripheral T Cell LymphomaStatus: Not yet recruiting, Estimated PCD: 2027-02-01
Product
BITR2101Clinical trial
An Exploratory Clinical Study to Investigate the Effect of autoSTEM-OA and alloSTEM-OA in Participants With Knee Osteoarthritis.Status: Not yet recruiting, Estimated PCD: 2024-11-01
Product
FenretinideProduct
ASTX660Clinical trial
A Phase I/II, Multicenter, Open-Label, Nonrandomized Study to Evaluate the Tolerability and Safety of ASTX660 and the Efficacy at the Recommended Dose of ASTX660 in Patients With Relapsed or Refractory T-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Product
BrentuximabClinical trial
A Phase 1/2, Open-label, Multi-center Study to Evaluate theSafety and Efficacy of Selinexor Combined With Chemotherapy orTislelizumab in Relapsed or Refractory Mature T and NK Cell LymphomaStatus: Recruiting, Estimated PCD: 2024-05-31
Product
TislelizumabProduct
ICEProduct
GEMOXClinical trial
A Multicenter, Open-label, Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Relapsed or Refractory Peripheral T Cell LymphomaStatus: Terminated, Estimated PCD: 2022-09-30
Product
AK104Clinical trial
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive LymphomasStatus: Not yet recruiting, Estimated PCD: 2028-07-01
Product
C7R.CD30.CAR-EBVST cellsClinical trial
PI3Kδ Inhibitor Linperlisib Combined With HDAC Inhibitor Chidamide Versus CHOP in Patients With Peripheral T-cell Lymphoma: a Multicenter, Open Label, Phase Ib/II StudyStatus: Recruiting, Estimated PCD: 2025-12-31
Product
Linperlisib and ChidamideClinical trial
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin LymphomaStatus: Completed, Estimated PCD: 2019-04-18
Clinical trial
Phase I Study of Carfilzomib for the Treatment of T-Cell LymphomaStatus: Completed, Estimated PCD: 2015-04-01
Product
carfilzomibProduct
BendamustineClinical trial
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma：a Single-Arm, Open Lable， Multicenter Clinical Trial（LINCH Study）Status: Recruiting, Estimated PCD: 2026-08-01
Product
LinperlisibClinical trial
Allogeneic Peripheral Blood Stem Cell Transplantation With Minimally Myelosuppressive Regimen of Pentostatin and Low-dose Total-body IrradiationStatus: Completed, Estimated PCD: 2008-12-30
Product
PentostatinProduct
Cyclosporine AProduct
Mycophenolate MofetilDrug
FilgrastimClinical trial
A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2016-12-28
Drug
prednisoneDrug
cyclophosphamideDrug
etoposideDrug
VincristineProduct
pralatrexateProduct
Gene expression analysisProduct
Nucleic Acid SequencingProduct
Mutation AnalysisProduct
Microarray analysisProduct
RNA analysisClinical trial
A Multicenter, Prospective and Single-arm Clinical Study on the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma (R/R PTCL) With Chidamide and DuvalisibStatus: Recruiting, Estimated PCD: 2024-12-31
Product
Chidamide + DuvillisibClinical trial
A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell TransplantStatus: Completed, Estimated PCD: 2024-02-02
Clinical trial
Pilot Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2024-11-01
Product
CPI 613Clinical trial
Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line TherapyStatus: Recruiting, Estimated PCD: 2025-04-30
Product
Systemic therapyClinical trial
Open-Label Extension Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects Who Relapsed After Complete Response on Study KW-0761-001Status: Completed, Estimated PCD: 2012-09-01
Product
KW-0761Clinical trial
A Phase I/II Study of Intratumoral Injection of Ipilimumab in Combination With Local Radiation in Melanoma, Non-Hodkgkin Lymphoma and Colorectal CarcinomaStatus: Terminated, Estimated PCD: 2014-11-01
Product
IpilimumabClinical trial
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Multi-center Phase II Study of CC486-CHOP in Patients With Previously Untreated Peripheral T-cell LymphomaStatus: Completed, Estimated PCD: 2020-03-25
Product
CC-486Product
CHOPClinical trial
A Prospective, Single-arm, Multicenter Clinical Study of the Combination of CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell LymphomaStatus: Recruiting, Estimated PCD: 2025-01-01
Product
CMOP+ChidamideClinical trial
A Randomized Controlled Clinical Trial Comparing Chidamide,Carmustine,Etoposide,Cytarabine and Melphalan With BEAM Regimen Combined With Autologus Hematopoietic Stem Cell Transplantation for the Treatment of Newly Diagnosed PTCLStatus: Recruiting, Estimated PCD: 2026-02-01
Product
C-BEAMProduct
BEAMClinical trial
A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2013-12-01
Product
ClofarabineClinical trial
A Phase II Study of Anti-Programmed Death-1(PD-1) Antibody Sintilimab Plus Histone Deacetylase(HDAC) Inhibitor Chidamide in Patients With Relapsed/ Refractory Peripheral T-cell LymphomaStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins LymphomaStatus: Completed, Estimated PCD: 2019-12-15
Product
TemsirolimusProduct
EtoposideDrug
DocetaxelProduct
HydrocortisoneProduct
CytarabineClinical trial
The Efficacy and Safety of Targeted Drug in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in the Treatment of Newly Diagnosed Peripheral T-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-04-20
Product
CHOP+XClinical trial
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCLStatus: Active (not recruiting), Estimated PCD: 2020-08-11
Product
romidepsinDrug
lenalidomideClinical trial
An Open-Label, Multicenter Phase IIa Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Puesta Mesylate for Injection for the Treatment of Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell LymphomaStatus: Recruiting, Estimated PCD: 2025-11-22
Product
Purinostat Mesylate